Moving from “Trial and Error” to Personalized Care
There are 400,000 Americans living with Multiple Sclerosis, a chronic condition that affects the central nervous system. However, MS onset, progression and response to treatment is very individualized and can range widely from person to person.
There are numerous MS drugs available, but their degree of benefit to each person may vary. The ability to predict how or if a particular person will respond to a given therapy could help doctors and individuals with MS better manage, and even get ahead of, their disease.
Around the country, people living with MS are joining the EMPOWER Study to help researchers develop an at-home fingerstick blood test that will help doctors monitor their patient’s MS disease activity, and make treatment choices based on that patient’s individual biology.